
Swiss pharmaceuticals giant Novartis has bought the remaining shares in US eyecare company Alcon it did not already own for $12.9 billion (£8.2 billion), thus sealing 100 per cent ownership.
Novartis had been trying to assume total ownership of Alcon since January, when it paid $28.1 billion for a 77 per cent stake in the US company from food giant Nestlé.
Alcon is famous for its contact lens solutions and is also a leader in intraocular lenses, tiny lenses that are implanted in the eye to correct focusing problems.










